在儿童中治疗高血症的管理
1University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Current opinion in pediatrics
|November 24, 2023
概括
儿童高胆血症的治疗需要及时的干预. 本综述涵盖了这种可能致命的疾病的原因,影响和当前/新疗法.
科学领域:
- 儿科脏病学 儿科脏病学
- 儿科重症监护 儿科重症监护
- 临床药理学 临床药理学
背景情况:
- 高血症是一种严重的电解质失衡,具有严重的健康后果.
- 目前的儿科高血症管理缺乏标准化.
- 有效的治疗对于预防危及生命的结果至关重要.
研究的目的:
- 为临床医生提供知识,以便及时有效地管理儿科高血症.
- 审查既有和新兴的治疗策略.
- 为了解决儿科高血症治疗方面的知识差距.
主要方法:
- 综合文献综述高卡血症管理.
- 分析现有的治疗指南.
- 对新型结合剂的评估.
主要成果:
- 已确定儿童高卡血症的原因和严重影响.
- 针对急性和慢性高血症的详细管理策略.
- 突出了新的口服药物,如帕蒂罗默和氧化环酸盐.
结论:
- 需要标准化的儿科高血症管理.
- 新型药物显示有前途,但需要进一步的儿科调查.
- 这一审查为改善临床实践提供了基础.
相关概念视频
Antihypertensive Drugs: Potassium-Sparing Diuretics
582
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
582
Heart Failure Drugs: Inotropic Agents
594
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
747
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
747
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Regulation of Sodium and Potassium
554
The regulation of sodium and potassium ion concentrations in the human body is a complex process governed primarily by hormones such as aldosterone, antidiuretic hormone (ADH), and atrial natriuretic peptide (ANP).
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
Sodium Regulation
Sodium ions make up approximately 90% of extracellular cations, with a normal blood plasma concentration of 136–148 mEq/L. A decrease in blood volume and pressure triggers the release of renin from granular cells in the juxtaglomerular complex (JGC), primarily...
554


